I'll quote SNY CC "Afrezza is not a commercially viable product in the U.S."
They poisoned the well!! (?intended)
Now, if Matt can "flush the well" and restart the water fresh...
Maybe the crops won't die from a drought (run out of cash).
STILL, It leaves the "gorilla in the room", Is Afrezza commercially viable?
If SNY had given 1/3 the effort, recources, and time (only 6 months), it had given ANY OTHER of its new products (think Prauluent), then I would think Afrezza could find it's market. I do not know why SNY terminate SO early, makes no sense to me (New CEO, competitive forces, poor clinical results, etc.??). None of this has really been proven. Heck, I wouldn't mind as much if SNY tried full-out to market it and then dumped it, at least I would know why, but c'mon, they dumped after 6 months, 6 months of marketing, a drug like this?!
Now Witz leaves, Lixilan looks shakey for FDA approval.....ironic?
There is no "superiority" for Afrezza, maybe better label though.
So, Can Matt and the new sales force get the water running again?
I am holding out for the last ditch effort from MNKD. Looks like we will know by end of 2016....IMO